Journals & Books Create account Sign in

Get Access Share Export

Ophthalmology
Volume 104, Issue 1, January 1997, Pages 137-142

A Comparison of Dorzolamide and Timolol in Patients with Pseudoexfoliation

and Glaucoma or Ocular Hypertension
Anders Heijl MD 1 , Ellen Strahlman MD 2, **, ***, Thordur Sverrisson MD 3, Olaf Brinchman-Hansen MD 4, Tuomo Puustjärvi MD 5, Robert
Tipping MS 2, **
Show more

https://doi.org/10.1016/S0161-6420(97)30348-0 Get rights and content

Purpose: The purpose of the study is to compare the efficacy and safety profile of 2.0% dorzolamide (three times daily)
and 0.5% timolol (twice daily) for up to 6 months in patients with glaucoma or ocular hypertension associated with
pseudoexfoliation. The additive effects of dorzolamide and timolol in patients requiring add-on therapy also was
evaluated.

Methods: This was a double-masked, randomized, parallel comparison study at 15 Scandinavian sites. One hundred
eighty-four patients with pseudoexfoliation and either glaucoma or ocular hypertension who were 21 to 85 years of age
were studied. The treatment groups were 2.0% dorzolamide three times daily and 0.5% timolol maleate twice daily.

Results: At 6 months, the mean percent reduction in intraocular pressure of 2% dorzolamide and 0.5% timolol was 24%
and 29%, respectively, at morning peak and 21% and 23%, respectively, at afternoon trough. The additional intraocular
pressurelowering effect of adding 2.0% dorzolamide twice daily to patients receiving timolol was 14% and 15%, at peak
and trough, respectively. There were no differences between treatment groups in the incidence of clinical adverse
experiences, and dorzolamide was not associated with the systemic adverse effects typically ascribed to the use of oral
carbonic anhydrase inhibitors.

Conclusion: Two percent dorzolamide (three times daily) was effective and well tolerated in patients with glaucoma or
ocular hypertension associated with pseudoexfoliation over the course of 6 months; 0.5% timolol (twice daily) had a
greater level of intraocular pressure-lowering activity than did dorzolamide, although the difference between the two
treatments became less pronounced during the study period. Finally, 2.0% dorzolamide (twice daily) produced additional
lowering of intraocular pressure when given with 0.5% timolol (twice daily).

Previous Next

Recommended articles Citing articles (45)

**
Dr. Strahlman and Mr. Tipping were employees of Merck & Co, Inc, the manufacturer of dorzolamide, at the time this study was conducted.

***
Dr. Strahlman currently is the Vice President of Corporate Medical Affairs for Bausch & Lomb.